Ovarian Cancer
15 competing products in clinical development for Ovarian Cancer.
Pipeline by Phase
Phase 12
Phase 1/25
Phase 26
Phase 32
All Products (15)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Trastuzumab Deruxtecan + Bevacizumab | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Trastzumab Deruxtecan + Bevacizumab + Platinum Based Chemotherapy | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| arzoxifene hydrochloride | Eli Lilly | Phase 2 | Completed | 35 |
| Prexasertib | Eli Lilly | Phase 2 | Completed | 35 |
| Enzalutamide 40 MG | Astellas Pharma | Phase 2 | Completed | 35 |
| Durvalumab + BA3011 + BA3021 + ENB003 + Toripalimab | BioAtla | Phase 2 | Recruiting | 32 |
| OSI-906 + Paclitaxel | Astellas Pharma | Phase 1/2 | Completed | 32 |
| decitabine | Eisai | Phase 1/2 | Completed | 32 |
| Farletuzumab + Carboplatin + Taxane + Farletuzumab-matched placebo | Eisai | Phase 3 | Terminated | 32 |
| pemetrexed + topotecan | Eli Lilly | Phase 1 | Completed | 29 |
| IMAB027 | Astellas Pharma | Phase 1 | Completed | 29 |
| Gemcitabine + Oxaliplatin + Bevacizumab | Eli Lilly | Phase 2 | Terminated | 27 |
| ASP0739 | Astellas Pharma | Phase 1/2 | Terminated | 24 |
| Lenvatinib + Carboplatin + Gemcitabine | Eisai | Phase 1/2 | Terminated | 24 |
| Azenosertib + Niraparib | Zentalis Pharmaceuticals | Phase 1/2 | Completed | 22 |